Publications by authors named "F Pesek"
Article Synopsis
- The study monitored the effectiveness of the infliximab biosimilar CT-P13 in treating patients with inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC), in the Czech Republic.
- Out of 52 patients treated, 50% of those with CD and 40.9% with UC achieved remission after 14 weeks, with significant improvements in disease activity indices and serum C-reactive protein levels.
- The study concluded that CT-P13 is effective in managing IBD, with a few reported adverse events, highlighting its potential as a treatment option.
Background: Nonsteroidal anti-inflammatory drugs are associated with upper gastrointestinal mucosal injury. Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active naproxen once absorbed. We hypothesized that with lesser topical exposure to naproxen from the prodrug, there would be reduced gastroduodenal mucosal injury compared with naproxen.
View Article and Find Full Text PDFPurpose: To develop an interactive Web site to help smokeless tobacco (ST) users to reduce or stop their ST use and pilot test it for feasibility, acceptability, and short-term outcomes.
Methods: An interactive, multiple-contact Internet ST cessation program was developed, refined based on feedback from 17 ST users, and pilot-tested for feasibility, acceptability, and short-term effects on the ST-related behavior and attitudes among baseball athletes attending 3 colleges in California. Consenting ST users completed a baseline questionnaire and enrolled on the Web site for help with stopping ST use.